文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

频率至关重要:HIV-1 耐药突变检测中 Sanger 与下一代测序的比较

Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

该研究纳入瑞士 HIV 队列研究中采样间隔 ≤7 天的 594 对 Sanger 与下一代测序序列(527 名参与者),比较不同变异检出阈值下 HIV 耐药突变检出一致性。结果显示阈值 ≥5% 时一致性良好(Cohen's kappa >0.80),低阈值下检出大量低丰度耐药突变,但阈值 <3% 时检出的低丰度突变可能多为测序错误。

要点

  • 阈值 ≥5% 时 Sanger 与 NGS 检出的 HIV 耐药突变一致性良好(Cohen's kappa >0.80)。
  • 低丰度 HIV 耐药突变检出率随阈值降低而升高:10%-25% 阈值下为 28/417(6.7%),1%-2% 阈值下为 293/812(36.1%)。
  • 作者认为阈值 <3% 时检出的低丰度耐药突变中相当一部分可能为测序错误,临床不应过度解读。

核心结论

  • Sanger 测序与 NGS 在检测 HIV 耐药突变方面总体一致性高,但 NGS 在低变异检出阈值下可检出大量低丰度耐药突变;作者认为阈值 <3% 时检出的低丰度耐药突变中相当一部分可能为测序错误,临床不应过度解读。

研究设计与样本

  • 研究纳入瑞士 HIV 队列研究(SHCS)中采样日期相差 ≤7 天且同时有 Sanger 和 NGS 序列的参与者,比较两种方法检出的 HIV 耐药突变及不同变异检出阈值下的一致性。

主要发现

  • 共纳入来自 527 名 SHCS 参与者的 594 对 Sanger 与 NGS 序列;男性占 80.5%,采样时 76.3% 未接受抗逆转录病毒治疗(ART naive),78.1% 的序列为 B 亚型。
  • 总体而言,变异检出阈值 ≥5% 时 HIV 耐药突变的 Cohen's kappa >0.80,一致性良好。
  • 低丰度 HIV 耐药突变检出率随阈值降低而升高:10%-25% 阈值下为 28/417(6.7%),1%-2% 阈值下为 293/812(36.1%)。
  • 低丰度 HIV 耐药突变在未接受 ART 的参与者中过度呈现,且大多数在既往采样序列中未检出,提示阈值 <3% 时测序错误率高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Next-generation sequencing (NGS) is gradually replacing Sanger sequencing (SS) as the primary method for HIV genotypic resistance testing. However, there are limited systematic data on comparability of these methods in a clinical setting for the presence of low-abundance drug resistance mutations (DRMs) and their dependency on the variant-calling thresholds. METHODS: To compare the HIV-DRMs detected by SS and NGS, we included participants enrolled in the Swiss HIV Cohort Study (SHCS) with SS and NGS sequences available with sample collection dates ≤7 days apart. We tested for the presence of HIV-DRMs and compared the agreement between SS and NGS at different variant-calling thresholds. RESULTS: We included 594 pairs of SS and NGS from 527 SHCS participants. Males accounted for 80.5% of the participants, 76.3% were ART naive at sample collection and 78.1% of the sequences were subtype B. Overall, we observed a good agreement (Cohen's kappa >0.80) for HIV-DRMs for variant-calling thresholds ≥5%. We observed an increase in low-abundance HIV-DRMs detected at lower thresholds [28/417 (6.7%) at 10%-25% to 293/812 (36.1%) at 1%-2% threshold]. However, such low-abundance HIV-DRMs were overrepresented in ART-naive participants and were in most cases not detected in previously sampled sequences suggesting high sequencing error for thresholds <3%. CONCLUSIONS: We found high concordance between SS and NGS but also a substantial number of low-abundance HIV-DRMs detected only by NGS at lower variant-calling thresholds. Our findings suggest that a substantial fraction of the low-abundance HIV-DRMs detected at thresholds <3% may represent sequencing errors and hence should not be overinterpreted in clinical practice.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Balakrishna S, Loosli T, Zaheri M, et al. Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1. J Antimicrob Chemother. 2023. PMID: 36738248. doi:10.1093/jac/dkac430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。